Key result
The AGT M235T and ACE I/D polymorphisms were not significantly associated with blood pressure response to atenolol, lisinopril, or nifedipine SR in patients with essential hypertension.
Why the study?
Do AGT M235T or ACE I/D polymorphisms predict blood pressure response to atenolol, lisinopril, or nifedipine in patients with untreated essential hypertension?
RCT (n=107)
crossover
Do AGT M235T or ACE I/D polymorphisms predict blood pressure response to atenolol, lisinopril, or nifedipine in patients with untreated essential hypertension?
Genetic polymorphisms in the renin-angiotensin system (AGT M235T and ACE I/D) do not predict blood pressure response to common antihypertensive drugs.
Answers are grounded in this paper and cite their sources.
Genotyping for AGT M235T or ACE I/D variants is not warranted to guide therapy; challenges candidate-gene hypotheses for response to these agents.
OBJECTIVE: To investigate whether the M235T polymorphism of the angiotensinogen (AGT) gene and the insertion/deletion (I/D) polymorphism of the angiotensin-1 converting enzyme (ACE) gene predict blood pressure response to different antihypertensive agents. DESIGN: Sixty-three patients with untreated essential hypertension were randomly assigned in a placebo-controlled crossover comparison to atenolol 50 mg once daily, lisinopril 10 mg once daily and nifedipine SR 20 mg twice daily, and the effect on blood pressure was assessed by ambulatory blood pressure monitoring (ABPM). In a further 44 patients, placebo-controlled ABPM data were available after treatment with a single agent (atenolol 50 mg once daily in 16 cases and lisinopril 10mg once daily in 28 cases). The change in systolic and diastolic blood pressure achieved by each agent was analysed for association with genotypes at the AGT and ACE gene loci. METHODS: Polymerase chain reaction (PCR) amplification of genomic DNA from each individual was used to identify the I/D polymorphism of the ACE gene. The M235T polymorphism of the AGT gene was detected by Tth111I digestion of PCR product. RESULTS: There was no significant association between response to any drug and either the AGT M235T or ACE I/D polymorphisms. CONCLUSIONS: The large variability between individuals in the observed blood pressure response to these agents cannot be attributed to the polymorphisms analysed at the ACE and AGT loci.
No takes yet. Share an insight, caveat, or question.
Dudley et al. (1996) conducted an RCT in untreated essential hypertension (n=107). Atenolol, lisinopril, and nifedipine SR vs. Placebo was evaluated on Change in systolic and diastolic blood pressure associated with AGT M235T and ACE I/D genotypes. The AGT M235T and ACE I/D polymorphisms were not significantly associated with blood pressure response to atenolol, lisinopril, or nifedipine SR in patients with essential hypertension.
Synapse has enriched 10 related papers. Consider them for comparative context: